eligibility_summary
Eligible: untreated CD20+ LBCL, IPI 2–5, ECOG 0–2, measurable lesion (>1.5 cm), tumor tissue, LVEF ≥50%, adequate counts, HIV‑ and SARS‑CoV‑2‑. Exclude: contraindication to Pola‑R‑CHP/glofitamab/anthracyclines, prior transplant, LBCL therapy (except steroids), immunotherapy/investigational therapy or mediastinal RT, current immunosuppression/high‑dose steroids, >G1 neuropathy, excluded lymphoma or CNS disease, major CV/CNS/liver disease, recent surgery, active infection/TB, HBV/HCV/HTLV‑1, chronic active EBV, HLH, PML, recent live vaccine.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase III randomized open-label trial in previously untreated CD20+ large B-cell lymphoma comparing: (1) Glofitamab + Pola-R-CHP vs (2) Pola-R-CHP. Glofitamab: CD20xCD3 bispecific T-cell–engaging antibody (IgG, 2:1) that recruits/activates T cells via CD3 to kill CD20+ B cells. Polatuzumab vedotin: anti-CD79b antibody-drug conjugate delivering MMAE to CD79b+ B cells, disrupting microtubules and inducing apoptosis. Rituximab: anti-CD20 monoclonal antibody mediating B-cell depletion (CDC/ADCC/apoptosis). Cyclophosphamide: alkylating chemotherapy causing DNA crosslinks. Doxorubicin: anthracycline/topoisomerase II inhibitor and DNA intercalator. Prednisone: glucocorticoid with lympholytic/anti-inflammatory effects. Targets/pathways: CD20, CD79b, CD3 (T-cell activation), microtubules, DNA replication/repair, topoisomerase II, glucocorticoid signaling.